{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:22:53Z","timestamp":1790706173051,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"DOI":"10.7759\/cureus.85970","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T05:45:46Z","timestamp":1749879946000},"source":"Crossref","is-referenced-by-count":4,"title":["Short-Term Effects of Tirzepatide in Obese Adults: A Real-World Prospective Study"],"prefix":"10.7759","author":[{"given":"Nikos","family":"Adamidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Desalermos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nektaria","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Adamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Koutrakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kyventidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki E","family":"Georgakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Adamidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60460-8","article-title":"Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"384","author":"Ng M","year":"2014","unstructured":"Ng M, Fleming T, Robinson M, et al.. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014, 384:766-81. 10.1016\/S0140-6736(14)60460-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67483-1","article-title":"Obesity","volume":"366","author":"Haslam DW","year":"2005","unstructured":"Haslam DW, James WP. Obesity. Lancet. 2005, 366:1197-209. 10.1016\/S0140-6736(05)67483-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14200","article-title":"Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes","volume":"23 Suppl 1","author":"Bray GA","year":"2021","unstructured":"Bray GA, Ryan DH. Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes. Diabetes Obes Metab. 2021, 23 Suppl 1:50-62. 10.1111\/dom.14200","journal-title":"Diabetes Obes Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1037\/amp0000517","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden TA","year":"2020","unstructured":"Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020, 75:235-51. 10.1037\/amp0000517","journal-title":"Am Psychol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun T","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, et al.. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018, 18:3-14. 10.1016\/j.molmet.2018.09.009","journal-title":"Mol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20 Suppl 1","author":"Nauck MA","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018, 20 Suppl 1:5-21. 10.1111\/dom.13129","journal-title":"Diabetes Obes Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas MK","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, et al.. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021, 106:388-96. 10.1210\/clinem\/dgaa863","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS- 3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik B","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al.. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS- 3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021, 398:583-98. 10.1016\/S0140-6736(21)01443-4","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.067264","article-title":"Body fat distribution and risk of cardiovascular disease: an update","volume":"126","author":"Despr\u00e9s JP","year":"2012","unstructured":"Despr\u00e9s JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012, 126:1301-13. 10.1161\/CIRCULATIONAHA.111.067264","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2012.06.010","article-title":"Sarcopenic obesity: a critical appraisal of the current evidence","volume":"31","author":"Prado CM","year":"2012","unstructured":"Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr. 2012, 31:583-601. 10.1016\/j.clnu.2012.06.010","journal-title":"Clin Nutr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15140","article-title":"Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: a post hoc assessment of the SURPASS clinical trial programme","volume":"25","author":"Pedersen SD","year":"2023","unstructured":"Pedersen SD, Giorgino F, Umpierrez G, et al.. Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: a post hoc assessment of the SURPASS clinical trial programme. Diabetes Obes Metab. 2023, 25:2553-60. 10.1111\/dom.15140","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.14","article-title":"Body composition measured by dual-energy X-ray absorptiometry half-body scans in obese adults","volume":"17","author":"Rothney MP","year":"2009","unstructured":"Rothney MP, Brychta RJ, Schaefer EV, Chen KY, Skarulis MC. Body composition measured by dual-energy X-ray absorptiometry half-body scans in obese adults. Obesity (Silver Spring). 2009, 17:1281-6. 10.1038\/oby.2009.14","journal-title":"Obesity (Silver Spring)"},{"key":"ref15","article-title":"Pharmacologic therapy for obesity","author":"Rodrigues Silva Sombra L","year":"2025","unstructured":"Rodrigues Silva Sombra L, Anastasopoulou C. Pharmacologic therapy for obesity. Rodrigues Silva Sombra L, Anastasopoulou C (ed): StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look M","year":"2025","unstructured":"Look M, Dunn JP, Kushner RF, et al.. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025, 27:2720-9. 10.1111\/dom.16275","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101636","article-title":"Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States","volume":"51","author":"Hankosky ER","year":"2025","unstructured":"Hankosky ER, Desai K, Chinthammit C, et al.. Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes Metab. 2025, 51:101636. 10.1016\/j.diabet.2025.101636","journal-title":"Diabetes Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez PJ","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024, 184:1056-64. 10.1001\/jamainternmed.2024.2525","journal-title":"JAMA Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26 Suppl 4","author":"Neeland IJ","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024, 26 Suppl 4:16-27. 10.1111\/dom.15728","journal-title":"Diabetes Obes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/375500-short-term-effects-of-tirzepatide-in-obese-adults-a-real-world-prospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T05:45:46Z","timestamp":1749879946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/375500-short-term-effects-of-tirzepatide-in-obese-adults-a-real-world-prospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.85970","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}